{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "086a0ffc",
   "metadata": {},
   "outputs": [],
   "source": [
    "from os import getcwd\n",
    "from niagads.csv_triples_parser.core import CSVTriplesParser, RDFTripleType\n",
    "file = \"./cadro-triples.txt\"\n",
    "defFile =\"./cadro-categories.txt\" # f\"{path}/cadro-categories.txt\"\n",
    "parser = CSVTriplesParser(file=file, definitionFile=defFile, parserType=RDFTripleType.CLASS_HIERARCHY)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "943bc8e8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'category': 'Molecular Pathogenesis and Physiology of Alzheimer’s Disease and Alzheimer’s Disease-related Dementias (AD/ADRDs)', 'definition': 'This category includes research focused on the molecular and physiological processes underlying Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) pathogenesis and their genetic and epigenetic determinants.'}, {'category': 'Diagnosis, Assessment, and Disease Monitoring', 'definition': 'This category includes research focused on the discovery, development, testing and validation (including through Autopsy) of tools and methods for diagnosing and monitoring individuals with AD and ADRDs from the preclinical phase of the disease through advanced dementia, including post-mortem analyses. These methods and tools include all types of novel and established biomarkers.'}, {'category': 'Translational Research and Clinical Interventions', 'definition': 'This category aims to capture projects focused on the identification, validation and development of potential targets (including small molecule, natural products, and biologics) for AD and ADRDs from early therapeutic discovery through late stage preclinical development and all stages of clinical testing. Also, included are projects focused on repurposing pharmacological agents already in use for other conditions as well as non-pharmacological interventions.'}, {'category': 'Populational Studies', 'definition': 'This category includes a listing of all of cohort and population studies (cross-sectional, cross-national, prospective, and longitudinal) that examine how a variety of genetic, lifestyle, and environmental, and social and behavioral risk factors may influence the incidence, prevalence, and clinical course of AD and ADRDs.'}, {'category': 'Dementia Care and Impact of Disease', 'definition': 'The research in this category includes projects aimed at improving the quality of care and quality of life for persons with dementia in a variety of care-giving settings (e.g., in the home, nursing home facilities, hospice programs) across diverse populations. This category also includes research focused on developing interventions that seek to alleviate the physical and emotional burden often associated with family or informal caregiving, which can include culturally tailored and technological interventions, as well as projects focused on assessing the economic and social impact of AD and ADRDs.'}, {'category': 'Research Resources', 'definition': 'The category includes a variety of resources used to conduct, translate, and disseminate high quality dementia research such as research centers, infrastructure (e.g., various cores), data and tissue repositories, and projects focused on generating disease models. Training and career development programs are also included in this category. Projects in this category may be double coded in Categories A-E and H, based on scientific relevance.'}, {'category': 'Consortia and Public Private Partnerships \\u200b\\u200b', 'definition': 'This category includes partnership enterprises that support major national and international efforts in AD and ADRD research. Projects included in this category may also be double coded in Categories A-F and H.'}, {'category': 'Brain Aging and Common Mechanisms Related to Dementias', 'definition': 'This category includes basic, translational and clinical research on processes and mechanisms of brain aging, and research that explores common mechanisms underlying different diseases that may contribute to our understanding of key concepts in dementia research.'}]\n"
     ]
    }
   ],
   "source": [
    "defs = parser.get_defintions()\n",
    "print(defs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "21eaea8f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "80c66357-cac9-5d9f-8410-dd31cf1378c7\n"
     ]
    }
   ],
   "source": [
    "from niagads.string_utils.core import generate_uuid\n",
    "\n",
    "x = generate_uuid('abc')\n",
    "print(x)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "534d5e41",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "@prefix niagads: <https://www.niagads.org/niagads#> .\n",
      "@prefix owl: <http://www.w3.org/2002/07/owl#> .\n",
      "@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .\n",
      "\n",
      "niagads: a owl:Class ;\n",
      "    rdfs:label \"\",\n",
      "        \"APP Processing\",\n",
      "        \"APP Structure and Function\",\n",
      "        \"APP and Amyloid beta Signaling\",\n",
      "        \"Advanced care directives/planning interventions in formal care settings (i.e., acute care systems, short stay program)\",\n",
      "        \"Air pollutants\",\n",
      "        \"Alpha-Synuclein\",\n",
      "        \"Alzheimer’s Disease Centers\",\n",
      "        \"Amyloid beta\",\n",
      "        \"Amyloid beta Clearance\",\n",
      "        \"Amyloid beta Structure, Assembly, and Aggregation\",\n",
      "        \"Amyloid beta-Mediated Pathogenesis\",\n",
      "        \"ApoE Structure and Function\",\n",
      "        \"ApoE and Lipid Neurobiology\",\n",
      "        \"ApoE in Abeta-Mediated Pathogenesis\",\n",
      "        \"ApoE in Pathogenesis Independent of Abeta\",\n",
      "        \"ApoE, Lipids and Lipoprotein Receptors\",\n",
      "        \"Apoptosis\",\n",
      "        \"Assessing quality of care/life of person with dementia\",\n",
      "        \"Astrocyte mediated\",\n",
      "        \"Atherosclerosis\",\n",
      "        \"Autophagy, Endocytosis and Membrane Trafficking\",\n",
      "        \"Autophagy-Mediated Cell Death\",\n",
      "        \"BBB and Neurovascular Unit\",\n",
      "        \"Basic Research\",\n",
      "        \"Biobanks\",\n",
      "        \"Bioinformatics\",\n",
      "        \"Blood-based Biomarkers\",\n",
      "        \"Brain Aging\",\n",
      "        \"Brain Aging and Common Mechanisms Related to Dementias\",\n",
      "        \"Brain Lipid Metabolism\",\n",
      "        \"C9ORF-72 and Progranulin\",\n",
      "        \"CNS Glucose\",\n",
      "        \"CSF Biomarkers\",\n",
      "        \"Calcium Signaling\",\n",
      "        \"Calcium-Mediated Cell Death\",\n",
      "        \"Calcium-Related Inflammation Mediators\",\n",
      "        \"Cardiovascular\",\n",
      "        \"Cardiovascular and Cerebrovascular dysfunction\",\n",
      "        \"Care coordination\",\n",
      "        \"Career Development (Ks, Travel Grants)\",\n",
      "        \"Caregiver assessments (assessing the psychological and physical health of caregiver health, quality of life, and support needs)\",\n",
      "        \"Caregiver tools, training and education (interventions for improving caregiver mastery and skills)\",\n",
      "        \"Caregiving / Workforce Shortage\",\n",
      "        \"Cell Cycle Re-Entry\",\n",
      "        \"Cell Death\",\n",
      "        \"Cell death\",\n",
      "        \"Cerebral Amyloid Angiopathy\",\n",
      "        \"Chemical pollutants\",\n",
      "        \"Circadian Rhythm\",\n",
      "        \"Circuits and Synapses\",\n",
      "        \"Clinical Ethics\",\n",
      "        \"Clinical Research and Epidemiology\",\n",
      "        \"Clinical Therapy Development for the Neuropsychiatric Symptoms of Dementia\",\n",
      "        \"Clinical Trial Design, including Recruitment/ Retention Strategies\",\n",
      "        \"Cognitive Training\",\n",
      "        \"Combination therapy\",\n",
      "        \"Common Mechanisms Related to Dementias\",\n",
      "        \"Complement Mediators of Inflammation\",\n",
      "        \"Conferences/Workshops/Symposia\",\n",
      "        \"Consortia\",\n",
      "        \"Consortia and Public Private Partnerships ​​\",\n",
      "        \"Couple-based and family-based interventions\",\n",
      "        \"Data Repositories\",\n",
      "        \"Dementia Care and Impact of Disease\",\n",
      "        \"Diagnosis, Assessment, and Disease Monitoring\",\n",
      "        \"Diet\",\n",
      "        \"Diffusion Tensor Imaging\",\n",
      "        \"Disease Models\",\n",
      "        \"Disease Pathway Identification (gene cluster and network analysis)\",\n",
      "        \"Drug Discovery (small molecules and biologics), including assay development\",\n",
      "        \"Dyslipidemia\",\n",
      "        \"Early-stage Clinical Drug Development (Phase I and Phase II Clinical Trials)\",\n",
      "        \"Emerging Biomarkers\",\n",
      "        \"Enabling Technologies (ex. iPS cells)\",\n",
      "        \"Endosomal/Lysosomal Dysfunction\",\n",
      "        \"Environmental Enrichment\",\n",
      "        \"Environmental Factors\",\n",
      "        \"Environmental Modifications and Technology Assisted Monitoring and Care\",\n",
      "        \"Environmental modifications\",\n",
      "        \"Epigenetic Regulators\",\n",
      "        \"Exercise\",\n",
      "        \"Exosome (ie. extracellular vesicles)\",\n",
      "        \"Faculty Recruitment\",\n",
      "        \"Family-based economic impact\",\n",
      "        \"Fellowships\",\n",
      "        \"Fluid Biomarkers\",\n",
      "        \"Functional MRI\",\n",
      "        \"Functional Validation of Genetic Risk and Protective Factors\",\n",
      "        \"Gene Editing\",\n",
      "        \"Gene-Gene and Gene Environment Interactions\",\n",
      "        \"Genetic (Micro-RNAs)\",\n",
      "        \"Genetic Architecture (Genetic variation and Chromosome Structure)\",\n",
      "        \"Genetic Data Sharing and Analysis\",\n",
      "        \"Genetics\",\n",
      "        \"Genome-Wide Association Studies and imputation analysis\",\n",
      "        \"Genomic\",\n",
      "        \"Growth Factors and Hormones\",\n",
      "        \"Growth Hormones\",\n",
      "        \"Gut-Brain Axis\",\n",
      "        \"Gut-Brain Axis and Microbiome\",\n",
      "        \"Health Disparities [Assess Inequality/equity (e.g., access and quality of care)]\",\n",
      "        \"Higher Mammals\",\n",
      "        \"Hormonal\",\n",
      "        \"Hypertension\",\n",
      "        \"Identification and Validation of Novel Targets\",\n",
      "        \"Identifying, Assessing and Improving Care and Quality of Life for Persons with Dementia\",\n",
      "        \"Identifying, Assessing and Improving Quality of Life and Care provided by Family or Informal Caregivers\",\n",
      "        \"Imaging Biomarkers\",\n",
      "        \"Immunity and Inflammation\",\n",
      "        \"Immunotherapy – Mechanisms of Action\",\n",
      "        \"Inflammation\",\n",
      "        \"Infrastructure (including equipment, construction, technology, etc..)\",\n",
      "        \"Innate Immunity\",\n",
      "        \"Insulin Resistance and Type II Diabetes\",\n",
      "        \"Intervention design for improving caregiver health and well-being (focus on family caregiver)\",\n",
      "        \"Intervention design for improving surrogate communication and decision making\",\n",
      "        \"Interventions in formal care settings (ie.acute care systems, short stay program)\",\n",
      "        \"Interventions in home or informal care settings (focused on person with dementia)\",\n",
      "        \"Invertebrates\",\n",
      "        \"Late-stage Clinical Drug Development (Phase II/III and III Clinical Trials)\",\n",
      "        \"Lipid-Mediated Signaling\",\n",
      "        \"Lipoprotein Receptors\",\n",
      "        \"Long term care services and supports (i.e. adult day center and in-home respite care; impact on on family / family caregiver)\",\n",
      "        \"Long-term services and supports supporting person(s) with dementia (e.g., in different home and community-based settings LTSS including adult day centers and in-home respite care)\",\n",
      "        \"Lymphatic/Glymphatic System Dysfunction\",\n",
      "        \"MR Microscopy\",\n",
      "        \"Metabolic Syndrome\",\n",
      "        \"Metabolism and Bioenergetics\",\n",
      "        \"Metabolomic\",\n",
      "        \"Metal pollutants\",\n",
      "        \"Microglia mediated\",\n",
      "        \"Mitochondrial Bioenergetics\",\n",
      "        \"Molecular Mechanisms of Neuroprotection and Resilience\",\n",
      "        \"Molecular Pathogenesis and Physiology of Alzheimer’s Disease and Alzheimer's Disease-related Dementias (AD/ADRDs)\",\n",
      "        \"Molecular Pathogenesis and Physiology of Alzheimer’s Disease and Alzheimer’s Disease-related Dementias (AD/ADRDs)\",\n",
      "        \"Multi-fluid Biomarkers\",\n",
      "        \"Multi-omics\",\n",
      "        \"Multi-target\",\n",
      "        \"Multimodal Biomarkers\",\n",
      "        \"Multiple Imaging\",\n",
      "        \"Myelin\",\n",
      "        \"Network Function and Failure\",\n",
      "        \"Neuroendocrine Mechanisms\",\n",
      "        \"Neurogenesis\",\n",
      "        \"Neurostimulation\",\n",
      "        \"Neurotransmitter Receptors\",\n",
      "        \"Neurotransmitter Receptors Structure and Function\",\n",
      "        \"Next generation Sequencing (i.e. WGS, Whole Exome)\",\n",
      "        \"Non-Pharmacological\",\n",
      "        \"Non-Pharmacological Interventions\",\n",
      "        \"Non-clinical Drug Development (small molecules and biologics), including toxicology studies\",\n",
      "        \"Non-clinical Proof of Concept for Non-Pharmacological Interventions\",\n",
      "        \"Normal Functions of Tau\",\n",
      "        \"Novel Analyses, Methodologies and Techniques for Biomarker Discovery and Validation\",\n",
      "        \"Nuclear Receptors\",\n",
      "        \"Nucleic acid-related “omics” studies (Epigenetics and Epigenomic and Transcriptomics, Expression Profiling)\",\n",
      "        \"Obesity\",\n",
      "        \"Other\",\n",
      "        \"Other Imaging Modalities\",\n",
      "        \"Other Pathogenic Mechanisms\",\n",
      "        \"Other Proteinopathies\",\n",
      "        \"Other Types of Cores or Centers (e.g., P01s, U01s, etc..)\",\n",
      "        \"Other technology assisted care\",\n",
      "        \"Oxidative Stress\",\n",
      "        \"PET Amyloid Imaging\",\n",
      "        \"PET Other Imaging\",\n",
      "        \"PET Tau Imaging\",\n",
      "        \"Palliative care/End-of-Life\",\n",
      "        \"Personal assessments (using wearable and mobile technology including cognitive, behavioral, functional reflecting changes in affective, social, decision-making, language/ speech, sensory and motor functions)\",\n",
      "        \"Personal device assisted care/wearables\",\n",
      "        \"Pharmacological\",\n",
      "        \"Populational Studies\",\n",
      "        \"Presenilin Biology\",\n",
      "        \"Presenilin-Mediated Cell Death\",\n",
      "        \"Prions\",\n",
      "        \"Professional and Career Development\",\n",
      "        \"Proteomic\",\n",
      "        \"Proteostasis\",\n",
      "        \"Proteostasis/Proteinopathies\",\n",
      "        \"Psychosocial Factors\",\n",
      "        \"Public Private Partnership\",\n",
      "        \"Re-Purposed Biomarkers\",\n",
      "        \"Remote monitoring tools/sensors\",\n",
      "        \"Repositories, Bioinformatics and Resources\",\n",
      "        \"Research Resources\",\n",
      "        \"Research Resources and Enabling Technologies to Accelerate Therapy Development\",\n",
      "        \"Retinal Imaging\",\n",
      "        \"Robotic-assisted care\",\n",
      "        \"Rodents\",\n",
      "        \"Role of Chemokines / Cytokines\",\n",
      "        \"SPECT\",\n",
      "        \"Saliva-based Biomarkers\",\n",
      "        \"Secretases\",\n",
      "        \"Selective Vulnerability\",\n",
      "        \"Sex Hormones\",\n",
      "        \"Sleep and Circadian Rhythm\",\n",
      "        \"Sleep-related\",\n",
      "        \"Societal-based economic impact\",\n",
      "        \"Socioeconomic Impact of Dementia\",\n",
      "        \"Staff training and professional development\",\n",
      "        \"Stress Hormones/HPA Axis\",\n",
      "        \"Structural MRI\",\n",
      "        \"Structure-Function Analysis\",\n",
      "        \"Synaptic Plasticity and Synaptic Dysfunction\",\n",
      "        \"Synaptic Plasticity/Neuroprotection\",\n",
      "        \"TDP-43 and FUS\",\n",
      "        \"TV/Video assisted care\",\n",
      "        \"Tau\",\n",
      "        \"Tau Phosphorylation, Metabolism, and Assembly\",\n",
      "        \"Tau-Mediated Pathogenesis (AD and ADRD)\",\n",
      "        \"Traditional assessments (including cognitive, behavioral, functional reflecting changes in affective, social, decision-making, language/ speech, sensory and motor functions)\",\n",
      "        \"Training Grants (e.g., T32)\",\n",
      "        \"Translational Bioinformatics and Multi-scale Modeling (ex. Drug repurposing)\",\n",
      "        \"Translational Infrastructure (ex. Model AD, ACTC)\",\n",
      "        \"Translational Research\",\n",
      "        \"Translational Research and Clinical Interventions\",\n",
      "        \"Ubiquitin Protease System\",\n",
      "        \"Unknown target\",\n",
      "        \"Urine Biomarkers\",\n",
      "        \"Vascular Etiology\",\n",
      "        \"Vasculature\",\n",
      "        \"Vertebrates\",\n",
      "        \"White Matter Lesions/Damage\",\n",
      "        \"category\",\n",
      "        \"iPS Cells\",\n",
      "        \"term\",\n",
      "        \"topic\" ;\n",
      "    rdfs:subClassOf owl:Thing,\n",
      "        niagads: .\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "parser.parse()\n",
    "x = parser.to_ttl()\n",
    "print(x)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
